IMPACT Therapeutics firma un acuerdo de licencia exclusiva con Pharmanovia

PartnershipsenaparibPositive

AI Analysis

Summary

IMPACT Therapeutics entered into an exclusive licensing agreement with Pharmanovia for senaparib in Europe, Middle East, North Africa, Australia, and New Zealand.

Outcome Details

Exclusive license agreement for senaparib in Europe, Middle East, North Africa, Australia, and New Zealand

Importance:7/10

Sentiment:

0.60

licensinggeographic expansionpartnership

Related Companies

$07630.HK

Read the original article

Published by PR Newswire Biotech on August 3, 2026 6:01 AM

Read Original